BALTIMORE, March 04, 2025 (GLOBE NEWSWIRE) — Irazú Oncology, LLC, a biotechnology company developing next-generation cancer immunotherapies, today announced the closing of bridge financing and key organizational developments, including the appointment of a Chief Medical Officer and expansion of its research facilities.
The financing will accelerate investigational new drug (IND) -enabling studies for Irazú’s lead candidate and support preparations for future clinical development. The company has appointed Mayukh Das, MBBS, as Chief Medical Officer and doubled its laboratory footprint at Connect Labs Baltimore (located in 4MLK within the University of Maryland BioPark in Baltimore, MD).
“This is a transformative period for Irazú as we prepare to advance our lead candidate into IND studies,” said …
